Show simple item record

dc.contributor.authorLopez, J
dc.contributor.authorShinde, R
dc.contributor.authorBurgess, MA
dc.contributor.authorSato, T
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorVan Tine, B
dc.contributor.authorRodon, JA
dc.contributor.authorDukes, J
dc.contributor.authorEaston, R
dc.contributor.authorMarshall, S
dc.date.accessioned2019-12-09T17:23:31Z
dc.date.available2019-12-09T17:23:31Z
dc.date.issued2019en
dc.identifier.citationLopez J, Shinde R, Burgess MA, Sato T, Thistlethwaite F, Van Tine B, et al. 1309TiP Trial in progress: First-in-human study of a novel anti-NY-ESO-1-anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101). Annals of Oncology. 2019;30(Supplement_5):532.en
dc.identifier.doi10.1093/annonc/mdz253.134en
dc.identifier.urihttp://hdl.handle.net/10541/622591
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz253.134en
dc.titleTrial in progress: First-in-human study of a novel anti-NY-ESO-1-anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDrug Development Unit, The Royal Marsden Foundation Trust and The Institute of Cancer Research, Londonen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T20:11:25Z


Files in this item

Thumbnail
Name:
mdz253.134.pdf
Size:
78.80Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record